A prospective observational study of immune-checkpoint inhibitor (Nivolumab) treatment in patients with non-small cell lung cancer
Latest Information Update: 01 Jan 2021
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 30 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 28 May 2016 New trial record